Heron Therapeutics Inc (NASDAQ:HRTX) – Investment analysts at Oppenheimer cut their FY2020 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued on Monday. Oppenheimer analyst D. Archila now forecasts that the biotechnology company will earn $1.22 per share for the year, down from their prior forecast of $1.32. Oppenheimer has a “Buy” rating and a $34.00 price objective on the stock. Oppenheimer also issued estimates for Heron Therapeutics’ FY2021 earnings at $3.30 EPS.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. The firm had revenue of $10.05 million during the quarter, compared to the consensus estimate of $9.00 million.
Several other brokerages have also commented on HRTX. BidaskClub lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Cantor Fitzgerald set a $40.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a report on Monday. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Cowen reissued a “buy” rating on shares of Heron Therapeutics in a report on Monday. Finally, Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a report on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $33.00.
Shares of HRTX stock traded up $0.75 on Wednesday, hitting $27.35. The company had a trading volume of 1,009,957 shares, compared to its average volume of 1,240,916. Heron Therapeutics has a one year low of $12.70 and a one year high of $32.70. The company has a market capitalization of $1,764.90, a price-to-earnings ratio of -7.43 and a beta of 1.87.
In other news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the transaction, the vice president now owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Barry D. Quart sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $24.75, for a total value of $2,475,000.00. Following the completion of the transaction, the chief executive officer now directly owns 167,993 shares of the company’s stock, valued at approximately $4,157,826.75. The disclosure for this sale can be found here. Insiders have sold 225,584 shares of company stock valued at $6,141,680 in the last three months. 19.93% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ellington Management Group LLC bought a new position in shares of Heron Therapeutics in the fourth quarter worth about $195,000. Pinnacle Associates Ltd. bought a new position in shares of Heron Therapeutics in the fourth quarter worth about $201,000. Jefferies Group LLC bought a new position in shares of Heron Therapeutics in the fourth quarter worth about $214,000. UBS Asset Management Americas Inc. bought a new position in shares of Heron Therapeutics in the fourth quarter worth about $230,000. Finally, Paloma Partners Management Co bought a new position in shares of Heron Therapeutics in the fourth quarter worth about $231,000.
TRADEMARK VIOLATION WARNING: “FY2020 Earnings Forecast for Heron Therapeutics Inc (HRTX) Issued By Oppenheimer” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2018/03/21/fy2020-earnings-forecast-for-heron-therapeutics-inc-hrtx-issued-by-oppenheimer.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.